Apellis Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO Apellis Pharmaceuticals is Cedric Francois, benoemd in Sep2009, heeft een ambtstermijn van 16.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.96M, bestaande uit 7.2% salaris en 92.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.15% van de aandelen van het bedrijf, ter waarde $ 60.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.6 jaar en 10.8 jaar.
Belangrijke informatie
Cedric Francois
Algemeen directeur
US$11.0m
Totale compensatie
| Percentage CEO-salaris | 7.24% |
| Dienstverband CEO | 16.7yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 8.6yrs |
| Gemiddelde ambtstermijn bestuur | 10.8yrs |
Recente managementupdates
Recent updates
APLS: Biogen Deal Terms And Mixed Ratings Will Guide Future Repricing
Analysts have raised the fair value estimate for Apellis Pharmaceuticals to about $40.93, citing Street research that combines several recent price target increases with a series of downgrades following Biogen's acquisition announcement, along with updated views on long-term P/E assumptions and risk. Analyst Commentary Street research around the Biogen acquisition announcement shows a split in how analysts are framing Apellis Pharmaceuticals, with some highlighting upside to long-term value and others focusing on execution and pricing risks.APLS: Balanced Biogen Deal And Mixed Ratings Will Shape Future Repricing
Apellis Pharmaceuticals' updated fair value estimate has shifted from $35.71 to $39.93 per share as analysts factor in higher long run P/E assumptions near 42x, alongside recent price target changes that include several upgrades, downgrades and target raises from firms such as Mizuho, JPMorgan, Morgan Stanley and RBC Capital. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split tape, with several firms lifting price targets while a cluster of downgrades points to fresh execution and valuation questions.APLS: Syfovre Outlook And Downgrade Wave Will Limit Future Repricing
Analysts now see fair value for Apellis Pharmaceuticals at about $35.71 per share, up from roughly $33.60, reflecting updated views on revenue growth, margins, discount rates, and a somewhat higher future P/E multiple after a mix of recent price target raises, initiations, and downgrades across the Street. Analyst Commentary Street research on Apellis Pharmaceuticals reflects a mixed but engaged view, with both bullish and bearish analysts adjusting targets, ratings, and coverage in response to recent reports and product updates.Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing
Mar 31APLS: Kidney Disease Launch And Index Adds Will Drive Future Repricing
Narrative Update on Apellis Pharmaceuticals The updated analyst price target framework now aligns with Street research that has recently adjusted Apellis price objectives in a roughly $18 to $44 range, with analysts pointing to demand trends for Syfovre and Empaveli, mixed views on growth beyond the current Q4 reporting period, and differing assumptions for revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Apellis Pharmaceuticals presents a mixed picture, with price targets spanning roughly US$18 to US$44 and a range of views on execution, product demand and future growth.
APLS: Future C3G Launch Execution Will Drive Bullish Re Rating Potential
Apellis Pharmaceuticals' updated analyst price targets cluster around the high teens to mid $40s, with modest adjustments up and down as analysts factor in the Q4 update, expectations for flat Syfovre pricing into FY26, progress in the C3G launch, and slightly revised assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Apellis Pharmaceuticals reflects a mixed but generally constructive stance, with price targets spanning from the high teens into the mid $40s and a blend of Neutral, Buy, and Overweight views.APLS: Kidney Disease Launch And Index Adds Will Support Future Repricing
Analysts have nudged their consolidated price target and fair value framework for Apellis slightly higher to $33.95, reflecting a blend of cautious optimism from fresh Neutral initiations and upgrades, along with mixed target revisions following the recent Q4 pre-announcement and C3G launch commentary. Analyst Commentary Recent research has focused on how Apellis is executing around its Q4 pre announcement and the early C3G launch, and what that means for valuation and risk.APLS: Kidney Disease Launch And Index Additions Will Support Future Share Recovery
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about US$1.44 per share, reflecting more cautious assumptions on revenue growth and profit margins, even as some recent research updates point to steady product launches and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split view, with some analysts focusing on product execution and others emphasizing revenue uncertainty and guidance gaps.APLS: Future C3G Renal Uptake Will Drive Bullish Re Rating Potential
Analysts have slightly increased their overall price expectations for Apellis, with recent Street targets clustering in a US$27 to US$45 range, as they balance cautious views on Syfovre revenue trends and guidance gaps against ongoing uptake in C3G and related renal indications. Analyst Commentary Recent Street research shows a mix of caution and optimism on Apellis, with several bullish analysts highlighting areas where they see the story improving around execution, revenue mix and potential upside to current expectations.APLS: Future Renal Indication Execution Will Drive Bullish Re Rating Potential
Analysts have trimmed their price targets for Apellis Pharmaceuticals, with recent cuts to US$45 and US$27. These moves reflect concerns about "flattish" Syfovre revenue and uncertainty around Empaveli's early renal indications, even as long term fair value assumptions and projected revenue growth in some models remain unchanged.APLS: Future Kidney Indication Uptake Will Drive Bullish Re-Rating Potential
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about $5 per share. They cite higher perceived risk, slower expected revenue growth from Syfovre and Empaveli, and somewhat lower long term margin assumptions, although several covering firms remain generally supportive.APLS: Kidney Disease Indication Launch Will Drive Share Price Recovery Ahead
Analysts have modestly lowered their average price target for Apellis Pharmaceuticals. They cite cautious outlooks on revenue growth and recent segment performance, with new targets ranging from $27 to $45 per share compared to prior targets up to $52.APLS: Future Revenue From Kidney Disease Expansion Will Drive Shares Higher
Analysts have modestly lowered their fair value estimate for Apellis Pharmaceuticals from approximately $36.50 to $35.39 per share. This adjustment is due to concerns over slower revenue growth and contracting profit margins following recent company updates.APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside
Analysts have lowered their average price target for Apellis Pharmaceuticals, reducing it by nearly $1 to $36.50. This adjustment reflects moderating revenue growth forecasts and a higher discount rate, although expectations for profit margin have marginally improved.FDA Label Expansion And SYFOVRE Will Unlock Future Value
Analyst price targets for Apellis Pharmaceuticals have edged lower to $37.47 as positive signals from Syfovre sales and pipeline opportunities are tempered by concerns over limited revenue guidance and commercial ramp uncertainties. Analyst Commentary Bullish analysts cite stabilization in the Geographic Atrophy (GA) market and optimism around the ongoing launches in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).FDA Label Expansion And SYFOVRE Will Unlock Future Value
The consensus analyst price target for Apellis Pharmaceuticals has risen modestly to $38.56, reflecting improving sentiment from stabilizing Geographic Atrophy market dynamics, continued Syfovre injection growth, and upside potential from Empaveli expansions, despite some concerns over Syfovre sales guidance and a possibly slower Empaveli ramp. Analyst Commentary Bullish analysts point to stabilizing Geographic Atrophy market dynamics and the ongoing launch initiatives in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) as a driver for upward price revisions.Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Jul 29
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers
May 09
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.Apellis Pharmaceuticals: A Mixed Bag
Mar 05Apellis: Saved By The October Data
Dec 25Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$22m |
| Sep 30 2025 | n/a | n/a | US$45m |
| Jun 30 2025 | n/a | n/a | -US$228m |
| Mar 31 2025 | n/a | n/a | -US$224m |
| Dec 31 2024 | US$11m | US$793k | -US$198m |
| Sep 30 2024 | n/a | n/a | -US$250m |
| Jun 30 2024 | n/a | n/a | -US$333m |
| Mar 31 2024 | n/a | n/a | -US$417m |
| Dec 31 2023 | US$10m | US$735k | -US$529m |
| Sep 30 2023 | n/a | n/a | -US$606m |
| Jun 30 2023 | n/a | n/a | -US$657m |
| Mar 31 2023 | n/a | n/a | -US$691m |
| Dec 31 2022 | US$9m | US$681k | -US$652m |
| Sep 30 2022 | n/a | n/a | -US$634m |
| Jun 30 2022 | n/a | n/a | -US$638m |
| Mar 31 2022 | n/a | n/a | -US$702m |
| Dec 31 2021 | US$9m | US$647k | -US$746m |
| Sep 30 2021 | n/a | n/a | -US$520m |
| Jun 30 2021 | n/a | n/a | -US$460m |
| Mar 31 2021 | n/a | n/a | -US$360m |
| Dec 31 2020 | US$9m | US$619k | -US$345m |
| Sep 30 2020 | n/a | n/a | -US$536m |
| Jun 30 2020 | n/a | n/a | -US$470m |
| Mar 31 2020 | n/a | n/a | -US$423m |
| Dec 31 2019 | US$4m | US$560k | -US$305m |
Compensatie versus markt: De totale vergoeding ($USD 10.96M ) Cedric } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.54M ).
Compensatie versus inkomsten: De vergoeding van Cedric is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Cedric Francois (53 yo)
16.7yrs
Tenure
US$10,957,451
Compensatie
Dr. Cedric Francois, M.D., Ph.D. is Co-Founder and Chairman of Liberate Medical, Inc. He serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and ha...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 16.7yrs | US$10.96m | 1.15% $ 60.3m | |
| Co-Founder & Director | 17.3yrs | US$492.47k | 0.62% $ 32.3m | |
| CFO & Treasurer | 8.6yrs | US$3.95m | 0.084% $ 4.4m | |
| General Counsel & Secretary | 12.3yrs | US$3.89m | 0.069% $ 3.6m | |
| Chief Medical Officer | 3.3yrs | US$4.41m | 0.028% $ 1.4m | |
| Co-Founder & Chief Scientific Officer | 16.7yrs | US$3.08m | 0.88% $ 46.2m | |
| VP, Corporate Controller & Chief Accounting Officer | 4.8yrs | geen gegevens | 0.018% $ 957.7k | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief People Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 4yrs | geen gegevens | geen gegevens | |
| Chief Technical Operations Officer | no data | US$3.02m | 0.027% $ 1.4m | |
| Executive Vice President of Commercial | no data | geen gegevens | geen gegevens |
8.6yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van APLS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 16.7yrs | US$10.96m | 1.15% $ 60.3m | |
| Co-Founder & Director | 16.7yrs | US$492.47k | 0.62% $ 32.3m | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 10.8yrs | geen gegevens | geen gegevens | |
| Independent Chairman of the Board | 12.8yrs | US$498.72k | 0.020% $ 1.1m | |
| Independent Director | 12.8yrs | US$484.97k | 0.025% $ 1.3m | |
| Member of AMD Scientific Advisory Board | 10.8yrs | geen gegevens | geen gegevens | |
| Member of PNH Scientific Advisory Board | 10.8yrs | geen gegevens | geen gegevens | |
| Member of Pulmonology Scientific Advisory Board | 10.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 6.1yrs | US$487.47k | 0.0044% $ 232.2k | |
| Independent Director | 16.2yrs | US$477.47k | 0.12% $ 6.3m | |
| Member of Pulmonology Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Pulmonology Scientific Advisory Board | 10.8yrs | geen gegevens | geen gegevens |
10.8yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van APLS zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.8 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/01 10:37 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Apellis Pharmaceuticals, Inc. wordt gevolgd door 34 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Eliana Merle | Barclays |